Mir Imran

Imran’s research interests are wide-ranging and include tissue engineering, gastroenterology, nephrology, neurology, orthopedics, congestive heart failure and artificial organs.

InCube Ventures is an early stage life science venture capital fund. Imran co-founded InCube Ventures with Andrew Farquharson and Wayne Roe. The fund invests in both InCube Labs’ companies as well as external companies. The fund primarily invests in novel therapies that have the potential to dramatically improve patient care.

2018: Named as one of the San Francisco Business Time and Silicon Valley Business Journal’s Upstart 50

2018: MedTech Innovation Catalyst Award, for outstanding and life-saving innovations in the medical field

In 2017, Imran announced the development of the Rani pill, a novel approach to the oral delivery of large drug molecules which previously have only been deliverable via injections. Imran describes this development as “a mini swallowable auto-injector” that delivers the drug directly into the highly vascular intestine wall, allowing the drug to be absorbed quickly into the bloodstream.

2017: Admitted to the National Academy of Engineering (US)

2015: Fellow of the National Academy of Inventors (US)

Keynote Speaker – Engineering in Medicine and Biology - UT Dallas - November 2007 UT Dallas Engineering in Medicine and Biology

2010: Neurotech Reports’ Gold Electrode Award for Most Valuable Financial Professional

Medtronic Distinguished Lecturer at Johns Hopkins BioMedical Engineering Day – May 2007 Johns Hopkins BioMedical Engineering Day Brochure – 2 May 2007

2005: Rutgers University Distinguished Engineer Award

In 1995, he developed a low-pressure balloon and aspirator system for use in catheter-based interventions. Imran was the first to articulate the concept of embolic protection during high-risk interventions, and his device became the primary innovation for Percusurge, which was acquired by Medtronic in December 2000.

Imran founded InCube Labs in 1995 after forming eight venture-backed medical device companies. Imran’s concept was that InCube would function as an applied research institute. Since the formation of InCube Labs, Imran has formed more than 20 life sciences companies. These include Rani Therapeutics, which was established in 2012 after beginning as a research project within InCube Labs.

In 1992, Imran invented a cooled RF ablation catheter for the treatment of ventricular arrhythmias. This invention became the initial product of Cardiac Pathways, and is now widely used by cardiac electro-physiologists.

He joined Intec Systems in 1980 and developed IP key to the development of the automatic implantable defibrillator, a device that has saved hundreds of thousands of lives, and has become a standard of care in cardiology. Intec Systems was acquired by Eli Lily, spun out to form Guidant, and acquired by Boston Scientific in 2006 for $27.5 billion.

After attending All Saints High School in Hyderabad, Imran moved to New Jersey in 1973 to attend Rutgers University. At Rutgers he received a BS in electrical engineering in 1976, followed by an MS in biomedical engineering. He then spent three years At Rutgers Medical School before deciding to leave and work on the first implantable cardioverter-defibrillator with Intec Systems.

Mir A. Imran (born 1956, Hyderabad, India), is an Indian medical inventor, entrepreneur and venture capitalist. Imran has formed over 20 medical device companies since the early 1980s and holds over 400 patents. He is known for his role in developing the world's first implantable cardiac defibrillator.